About the Centennial of Spring
Deeply engaged in autologous stem cell technology research for 25 years
Professional experimental platforms and continuous innovation capabilities
Reliable technology solutions for the healthcare industry
Company Profile
Shenzhen Chunzhu Hundred Years Stem Cell Technology Co., Ltd. is headquartered in Shenzhen and specializes in...Small-molecule-induced generation of autologous stem cellsA life sciences company focused on R&D and commercialization.
The company possesses independently developed and ownedPatent ProtectionOur core technology enables the efficient, large-scale production of autologous stem cells from patient blood. With 25 years of expertise in small-molecule-induced autologous stem cell technology and industrialization, we have built a robust R&D and translational capability to produce up to12 Types of Autologous Stem Cellsmanufacturing, with technical applications spanning basic research, clinical studies, and health management across diverse scenarios.
The company is deeply advancing collaborative innovation between industry, academia, and research institutions by jointly establishing a partnership with the Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences.Stem Cell Innovation ConsortiumAccelerate the development of new biopharmaceutical technologies and their clinical translation.
Leveraging its core technology of induced autologous hematopoietic stem cells, Chunzhu Century will continue to advance clinical research on these biomedical innovations across multiple areas, including systemic lupus erythematosus, post-myocardial infarction complications, pulmonary fibrosis, post-stroke sequelae, and diabetes.
Dedicated to advancing research in autologous stem cell technology
Capable of large-scale preparation of multiple types of autologous stem cells
Jointly established a stem cell innovation consortium with the Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences
Advance clinical research on emerging technologies for stroke sequelae, diabetes, and related conditions.
Core Technologies
Chunzhu Century: Small-Molecule-Induced Artificial Autologous Stem Cell Production and Preparation Technology
Chunzhu Century Autologous Stem Cell Production and Preparation Technology, Full Name"Spring Century: Small-Molecule-Induced Production Technology for Artificial Autologous Stem Cells"Processed and cultured using advanced molecular biology and cell growth regulation technologies, featuring a small-molecule protein complex formulation.
The technology uses blood cells as raw material, reactivating and activating specific stem cell regulatory genomes that were previously silenced. This induces the blood cells to undergo reverse differentiation, regenerating new autologous stem cells.
This autologous stem cell production technology, which uses massive quantities of somatic cells as raw materials, is a form of chemically induced non-genetic reprogramming."Original Autologous Stem Cells"A high-efficiency and secure autologous stem cell technology and product.
Next-generation high-potency stem cell preparation technology
Human adult cells can be reprogrammed to an earlier developmental stage using chemical small molecules, reverting them into autologous induced stem cells.
Chemical small-molecule induction to avoid transgenic safety risks
Chunzhu's Century Autologous Stem Cell Production and Preparation Technology offers significant advantages over traditional virus-induced methods. Chemical small molecules do not integrate into the genome, are simple to operate, fast, efficient, and stable. Furthermore, they eliminate safety concerns associated with traditional genetic modification, providing a stronger safety foundation for clinical applications.
Physiological reverse differentiation control without introducing exogenous genes
This technology leverages physiologically and near-physiologically accurate reverse differentiation regulation of cellular gene expression. It requires no viral vectors, enabling rapid production of large quantities of diverse autologous pluripotent stem cells. The resulting stem cells retain their original DNA sequences without recombination, truncation, or insertion of foreign genes, ensuring superior application safety.
Large cell size, high potential, and rigorous monitoring.
Stem cells produced using this technology offer large-scale cell yields and high differentiation potential. They enable precise, rigorous, and rapid repeated monitoring based on characteristic phenotypes. Additionally, these cells are young, safe, carry low risks of immune rejection, and raise minimal ethical or legal concerns.
Fully manufacturable, storable, and applicable across the entire lifecycle.
This technology enables individuals at any life stage to produce and store their own autologous stem cells, making them practically applicable for treating personal diseases, anti-aging care, and generating autologous tissues and organs in vitro.
Core Team
Dr. Lin Xiongbin
Founder
Senior expert in autologous stem cell technology; inventor of the patented proprietary series for chemically induced production of autologous stem cells; recipient of Germany's highest distinction for outstanding medical doctoral thesis (1994 years).
View details
Dr. Lin Yiguang
Chief Scientist
Selected for China's National Major Talent Program; Tenured Professor at the University of Technology Sydney (UTS), Australia. Previously held positions at prestigious universities worldwide, including Yale University and the University of Michigan.
View details
Dr. Xiaoxing Liao
Chief Medical Officer (CMO)
Senior expert in emergency medicine, disaster medicine, and cardiology; Level 2 Professor at Sun Yat-sen University; Lead of a National Key Clinical Specialty
View detailsTechnology Evolution
Seven Generations of Autologous Stem Cell Technology and Key Company Milestones
Industrialization Journey
2002Industry LaunchNanning Regenerative Cell Transplantation Center Established
In 2002, Dr. Lin Xiongbin, the company's founder, established Nanning Regenerative Cell Transplantation Center—the first cell transplantation treatment center in Guangxi and one of China's earliest stem cell therapy centers—in Nanning, Guangxi.
2004Clinical TranslationEstablishment of Guilin Shengzhiyuan Stem Cell Transplantation Specialized Hospital
In 2004, Dr. Lin Xiongbin founded China's first stem cell transplantation hospital—Guilin Shengzhiyuan Stem Cell Transplantation Hospital—in Guilin, China.
2012Capital EmpowermentInvesting in a Hong Kong Stock Exchange-listed company through autologous hematopoietic stem cell technology
In 2012, Dr. Lin Xiongbin, the company's founder, invested in Hong Kong Life Science & Technology Group through its autologous hematopoietic stem cell technology project, making it the first listed stem cell company in Hong Kong.
2024Scale deploymentGuangzhou Nansha Establishes Chunzhu Century Regenerative Medicine
Founded in 2024 at Nansha, Guangzhou, Chunzhu Century Regenerative Medicine aligns with the national strategy for innovative regenerative medicine technologies and leverages Nansha's pioneering policies on stem cell applications.
2025Platform UpgradeCollaborated with the Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, to establish a stem cell innovation consortium team.
In 2025, in accordance with Order No. 818, we partnered with the Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, to establish a stem cell innovation consortium. We collaborated with Grade 3A hospitals to initiate compliant Investigator-Initiated Trials (IITs) and submit required notifications, advancing our technology into a new phase of standardized research and clinical translation.
Brand Honors
Shenzhen Advanced Institute of Technology, Chinese Academy of Sciences - Cell Stem Cell Innovation Consortium Team
First Adult Autologous Stem Cell Demonstration Repository
National High-Tech Enterprise
10+ autologous stem cell production patents/proprietary technologies
ISO001 Quality Management System Certification
GMP Laboratory Environment Certification
12 autologous stem cell banks registered
12 types of autologous stem cell preparation centers registered
2019/2nd China New Unicorn Competition – Most Promising Growth Unicorn
Vice-Chairman Unit of the First Council of Shenzhen Association of Experts and Talents
Nomination Letter for the Second China Brand Summit – China Brand Annual Awards
Designated Health Service Provider for the 3rd China Health Industry Conference
China National Base for Large-scale Stem Cell Research in Big Health
Proprietary Patent
Methods for preparing autologous hematopoietic stem cells
Stem cell-based biological growth observation equipment for gastric cancer treatment
Freezer Storage Box
Method for generating human blood-derived autologous retinal stem cells via reverse differentiation of peripheral blood mononuclear cells
Century Stem Cell Flow Cytometry Control Software V1.0
Century Stem Cell Cryobank Management Software V1.0
Autologous Female Reproductive Stem Cell Test Report
Autologous NK Immune Cell Test Report
